Biodexa Pharmaceuticals (BDRX) News Today $4.40 +0.12 (+2.80%) As of 03:59 PM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Biodexa Pharmaceuticals files to sell 35.875M ADS for holdersJanuary 17, 2025 | markets.businessinsider.comBiodexa Pharmaceuticals PLC Unsponsored ADR (BDRX) Moves to Buy: Rationale Behind the UpgradeJanuary 4, 2025 | msn.comBiodexa Pharmaceuticals Adjusts Share Value Amid Drug Development FocusDecember 5, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals announces result of general meetingNovember 23, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals PLC: Result of General MeetingNovember 22, 2024 | finanznachrichten.deResult of General MeetingNovember 22, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXNovember 18, 2024 | prnewswire.comBiodexa Pharmaceuticals Secures Nasdaq Listing ComplianceNovember 13, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals regains Nasdaq complianceNovember 13, 2024 | markets.businessinsider.comBiodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Regains Compliance For Continued Listing on NasdaqNovember 12, 2024 | globenewswire.comBiodexa Pharmaceuticals Plans Strategic Share Value AdjustmentNovember 9, 2024 | markets.businessinsider.comNotice of General MeetingNovember 7, 2024 | globenewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXNovember 2, 2024 | prnewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 29, 2024 | globenewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 28, 2024 | businesswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 27, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXOctober 25, 2024 | prnewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 23, 2024 | globenewswire.comBDRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation Into Biodexa Pharmaceuticals Plc and Encourages Investors to Contact the FirmOctober 20, 2024 | businesswire.comBiodexa ADRs Rise After Successful Appeal of Nasdaq DelistingOctober 17, 2024 | marketwatch.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biodexa Pharmaceuticals Plc - BDRXOctober 17, 2024 | prnewswire.comLost Money on Biodexa Pharmaceuticals Plc (BDRX)? Contact Levi & Korsinsky Regarding an Ongoing InvestigationOctober 16, 2024 | stockhouse.comBiodexa Pharmaceuticals PLC: Biodexa Announces Successful Appeal of Nasdaq DelistingOctober 16, 2024 | finanznachrichten.deBiodexa Pharmaceuticals Stock Is Soaring After The Close: What's Driving Shares Higher?October 16, 2024 | benzinga.comBiodexa Announces Successful Appeal of Nasdaq DelistingOctober 15, 2024 | globenewswire.comFreightCar America (NASDAQ:RAIL) Stock Quotes, Forecast and News SummaryOctober 8, 2024 | benzinga.comBiodexa Pharmaceuticals (NASDAQ:BDRX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comBiodexa reports survival rates in glioblastoma studyOctober 6, 2024 | uk.investing.comBiodexa reports updated Phase 1 data from glioblastoma studyOctober 4, 2024 | msn.comBiodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent GlioblastomaOctober 4, 2024 | globenewswire.comInterim results for the six months ended June 30, 2024September 26, 2024 | globenewswire.comADR Ratio ChangeSeptember 19, 2024 | globenewswire.comBiodexa secures full access to cancer research grantSeptember 18, 2024 | uk.investing.comAnnounces Payment of $3.0MM Final Match Payment Enabling Access to Remainder of $17.0MM CPRIT GrantSeptember 16, 2024 | finance.yahoo.comReceipt of Nasdaq Delisting Determination - Plans to AppealAugust 30, 2024 | globenewswire.comBiodexa Pharmaceuticals files for 4.35B ordinary shares for holdersAugust 12, 2024 | msn.comEuropean Equities Traded in the US as American Depositary Receipts Flat in Monday TradingAugust 12, 2024 | msn.comAnnounces Closing of $5.0 Million Registered Direct Offering and Concurrent Private PlacementJuly 23, 2024 | globenewswire.comAnnounces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private PlacementJuly 19, 2024 | globenewswire.comWhy Is Biodexa Pharmaceuticals (BDRX) Up 56% Today?July 11, 2024 | investorplace.comPositive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024July 2, 2024 | globenewswire.comBiodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP)June 24, 2024 | globenewswire.comResults of Annual General MeetingJune 13, 2024 | globenewswire.comTwelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in BarcelonaJune 10, 2024 | globenewswire.comBiodexa Pharmaceuticals Stock Is Tumbling Wednesday: What's Going On?May 22, 2024 | msn.comGold Moves Lower; Macy's Boosts 2024 ForecastMay 22, 2024 | msn.comBiodexa Announces $7 Million of Gross Proceeds from Warrant ExercisesMay 22, 2024 | globenewswire.comWhat's Going On With Biodexa Pharmaceuticals Stock?May 21, 2024 | msn.comBiodexa rallies 80% on positive Phase 2 data for eRapaMay 21, 2024 | msn.comPositive Statistically Significant Phase 2 Clinical Trial Results of Biodexa’s Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for Presentation at the 2024 Digestive Disease Week Annual MeetingMay 21, 2024 | finance.yahoo.com Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address BDRX Media Mentions By Week BDRX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BDRX News Sentiment▼0.000.57▲Average Medical News Sentiment BDRX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BDRX Articles This Week▼11▲BDRX Articles Average Week Get Biodexa Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for BDRX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies TransCode Therapeutics News Today Bon Natural Life News Today Galmed Pharmaceuticals News Today Panbela Therapeutics News Today Virpax Pharmaceuticals News Today Eterna Therapeutics News Today Psyence Biomedical News Today Oncternal Therapeutics News Today 180 Life Sciences News Today Trevena News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BDRX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredThis coin could surge during Trump’s first week in office.Juan has never had a losing trade on Bitcoin. And he booked gains of 312% on Chainlink … Now, he says one v...Weiss Ratings | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodexa Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Biodexa Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
